Protein-based therapeutics promise to significantly improve medical outcomes, but many are expensive to produce in recombinant form or difficult to safely isolate from natural sources. At Ventria Bioscience, we are solving this problem by producing highly pure, biologically active recombinant therapeutic proteins with high efficiency. With one therapeutic candidate in phase 2 clinical trials and others in active clinical development, our goal is to make the routine use of recombinant protein therapies a reality for all.
Ventria Bioscience's lead therapeutic candidate is VEN100, containing recombinant human lactoferrin. Human lactoferrin is a principal protein component of human breast milk contributes to the establishment of a healthy infant digestive tract.Learn More
|»||VEN120||Inflammatory bowel disease|
Inflammatory Bowel Disease (IBD) affects 1.5 million people in the United States, and of those nearly half suffer from ulcerative colitis (UC). This condition is generally caused by a combination of genetic and environmental factors that lead to an over-reactive immune response in the large intestine.Learn More
Approximately 20% of American women older than age 50 have the thinning of bone tissue and loss of bone mineral density that are the hallmarks of osteoporosis.Learn More
|»||VEN150||HIV-associated chronic inflammation|
|»||VEN160||Unexplained anemia in the elderly|